Cite
HARVARD Citation
Adomi, M. et al. (2022). Letter: potential selection bias in the real‐world comparison of ustekinumab versus vedolizumab as a second‐line treatment for Crohn's disease. Alimentary pharmacology & therapeutics. 55 (8), p. 1069. [Online].